Home Press Release Takeda launches mobile application to support patient for treatment of genetic diseases

Takeda launches mobile application to support patient for treatment of genetic diseases

by News PHM
The XPERT EASE App will support HCPs with dose calculation for the treatment of patients with  Lysosomal Storage Disorders
Mumbai, February 26, 2021: Takeda India, part of the Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, launched the ‘XPERT EASE’ application. The application is developed for the exclusive use of healthcare professionals to address awareness-related challenges and enable an efficient digital ecosystem for disease updates and dose calculation for improved management of patients with rare lysosomal storage disorders.
Doctors’ screening, diagnosis, and treatment of genetic diseases have often been identified as challenging, including advising the dosage of medicines specific to patients’ individual needs. The XPERT EASE is designed to keep in mind such challenges while managing lysosomal storage disorders.
On the occasion of the launch, Dr. Sandeep Arora, Medical Affairs Head- Takeda India, said, “At Takeda, we are keen to enable faster diagnosis and access of patients to our medicines and innovative therapies. The XPERT EASE application enables healthcare professionals to raise suspicion index, leading to early diagnosis and better disease management. As we move forward in our commitment to patients and HCPs, we seek to drive collaborations across the country in ensuring that patients benefit from our pioneering efforts.”
XPERT EASE safeguards dosage accuracy and reduces the incidence of error, thereby helping physicians develop personalized dosing regimens tailored to their patients’ specific needs diagnosed with Lysosomal Storage Disorders. Healthcare professionals can access the applications through the Apple App Store and Google Play Store.
Ends
About Takeda India
Takeda India is part of Takeda Pharmaceutical Company Limited’s group of companies. Locally, the company currently focuses on the areas of Rare Diseases, including Hemophilia and Lysosomal Storage Disorders and plasma-derived therapies. Takeda has a presence across the Indian subcontinent, including in Sri Lanka, Nepal, and Bangladesh.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas:Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.
For more information, visit https://www.takeda.com.

Related Articles